Baxter to Invest $1 Billion on Gammagard Growth: Alleged Threat remains

On October 10th, 2012 Forbes reported that Baxter International decided to spend more than $1 billion on capital investments to support growth of Gammagard and other plasma-derived products. Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease. A new study presented on July 17th, 2012, at the Alzheimer's Association International Conference 2012 in Vancouver revealed Alzheimer's disease symptoms long-term (three-year) stabilization with Gammagard. At the end of February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Gammagard severe adverse events. [http://www.attorneyone.com/gammagard-lawsuits/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Gammagard: severe adverse events threat

Gammagard: severe adverse events threat

as many as 1,000 cases of hepatitis C could have been linked to use of Gammagard

San Diego, CA (PRWEB) October 16, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Gammagard side effects. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On October 10th, 2012 Forbes reported that Baxter International decided to spend more than $1 billion on capital investments to support growth of Gammagard and other plasma-derived products. Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease. Gammagard is gaining more attention and it is in a late-stage clinical trial as a potential Alzheimer’s treatment. A new study presented on July 17th, 2012, at the Alzheimer's Association International Conference 2012 in Vancouver revealed Alzheimer's disease symptoms long-term (three-year) stabilization with Gammagard.

At the end of February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. In July 1995, the FDA said that as many as 1,000 cases of hepatitis C could have been linked to use of Gammagard.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Gammagard, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Gammagard remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In August 2012, Baxter announced that it will discontinue manufacturing Gammagard S/D as of December 2012, as reported by the Immune Deficiency Foundation.

If you have recently been diagnosed with Hepatitis C and you took Gammagard, you might be able to file a Gammagard lawsuit.

AttorneyOne.com has further information on Gammagard lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/10/prweb9987173.htm.